Your Article Summary
See Latest ArticlesA phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy
Annals of Oncology, 06/29/09
Maemondo M et al. - Palonosetron at doses of 0.25 and 0.75 mg was shown to be effective in preventing chemotherapy-induced nausea and vomiting with high CR rates of patients treated with HEC in Japan. All tested doses of palonosetron were tolerated well.
Related Articles
Palonosetron in Prevention of Nausea and Vomiting After Highly Emetogenic Chemotherapy Before Haematopoietic Stem Cell Transplantation--Single Center Experience
Transplantation Proceedings, 11/16/09
Relevance Score: 83%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Clinical Cancer Research, 12/11/09
Radiation Therapy for Rectal Cancer: Current Status and Future Directions
Cancer Control, 12/11/09
Current Progress in Targeted Therapy for Colorectal Cancer
Cancer Control, 12/11/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Unanticipated toxicities from anticancer therapies: Survivors perspectives
Supportive Care in Cancer, 12/11/09
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: A double-blind, randomised trial
The Lancet Oncology - Online First, 12/09/09
Effects of functional electrical stimulation on dysphagia caused by radiation therapy in patients with nasopharyngeal carcinoma
Supportive Care in Cancer, 12/09/09